GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Cyclically Adjusted Price-to-FCF

Trinity Biotech (Trinity Biotech) Cyclically Adjusted Price-to-FCF : (As of Apr. 30, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Trinity Biotech Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Trinity Biotech's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Cyclically Adjusted Price-to-FCF Chart

Trinity Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Trinity Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Trinity Biotech's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Trinity Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's Cyclically Adjusted Price-to-FCF falls into.



Trinity Biotech Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Trinity Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Trinity Biotech's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.689/120.7077*120.7077
=-0.689

Current CPI (Sep. 2023) = 120.7077.

Trinity Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -1.656 99.875 -2.001
201403 -0.880 100.573 -1.056
201406 -0.392 100.773 -0.470
201409 -0.248 100.474 -0.298
201412 -0.708 99.576 -0.858
201503 -0.711 99.975 -0.858
201506 -1.079 100.573 -1.295
201509 -0.124 100.274 -0.149
201512 -0.741 99.676 -0.897
201603 -0.663 99.676 -0.803
201606 -0.864 101.072 -1.032
201609 -0.030 100.274 -0.036
201612 -0.494 99.676 -0.598
201703 -0.826 100.374 -0.993
201706 0.046 100.673 0.055
201709 0.065 100.474 0.078
201712 -0.568 100.075 -0.685
201803 -0.626 100.573 -0.751
201806 0.000 101.072 0.000
201809 -0.263 101.371 -0.313
201812 -0.632 100.773 -0.757
201903 -0.611 101.670 -0.725
201906 -0.331 102.168 -0.391
201909 0.020 102.268 0.024
201912 -0.637 102.068 -0.753
202003 -0.541 102.367 -0.638
202006 -0.038 101.769 -0.045
202009 0.824 101.072 0.984
202012 3.007 101.072 3.591
202103 0.703 102.367 0.829
202106 -0.242 103.364 -0.283
202109 -0.060 104.859 -0.069
202112 0.444 106.653 0.503
202203 -0.653 109.245 -0.722
202206 -0.550 112.734 -0.589
202209 -0.085 113.431 -0.090
202212 0.091 115.425 0.095
202303 -0.439 117.618 -0.451
202306 -0.651 119.611 -0.657
202309 -0.689 120.708 -0.689

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Trinity Biotech  (NAS:TRIB) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Trinity Biotech Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (Trinity Biotech) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.